Stock ACLX ARCELLX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Arcellx, Inc.

Equities

ACLX

US03940C1009

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
52.02 USD -0.42% Intraday chart for Arcellx, Inc. +0.23% -6.27%
May. 31 Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target MT
May. 15 Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target
MT
Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating
MT
Transcript : Arcellx, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
Evercore ISI Starts Arcellx With Outperform Rating
MT
Arcellx : IMMagine-3 Multi-center, Global, Phase 3 Randomized Control Clinical Trial Design
PU
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
BU
Arcellx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ACLX) ARCELLX Posts Q1 Revenue $39.3M
MT
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
CI
Arcellx Provides First Quarter 2024 Financial Results
BU
Arcellx to Participate in Two Upcoming Investor Conferences
BU
Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing
MT
Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing
MT
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing
MT
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing
MT
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
BU
Arcellx Insider Sold Shares Worth $633,582, According to a Recent SEC Filing
MT
Needham Raises Arcellx Price Target to $81 From $72, Maintains Buy Rating
MT
Morgan Stanley Initiates Arcellx With Overweight Rating, $81 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACLX Stock
  4. News Arcellx, Inc.